Ultragenyx is trading at $15.88, up 5.37%, alongside biotech stocks as the XBI rose 2.10% during Tuesday’s regular session; no report directly attributed the October 20 move to new company news.
- On October 19, the company reached a DOJOLVI patent settlement allowing Navinta generic entry starting in 2033.
- A news report said shares rose 2.3% in Monday trading after the announcement, but that does not establish the reason for Tuesday’s additional gain.